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To identify new host factors that modulate the replication of
influenzaA virus, we performed a yeast two-hybrid screen using
the cytoplasmic tail of matrix protein 2 from the highly patho-
genic H5N1 strain. The screen revealed a high-score interaction
with cyclin D3, a key regulator of cell cycle early G1 phase.
M2-cyclinD3 interactionwas validated throughGSTpull-down
and recapitulated in influenza A/WSN/33-infected cells.
Knockdown of Ccnd3 by small interfering RNA significantly
enhanced virus progeny titers in cell culture supernatants.
Interestingly, the increase in virus production was due to
cyclin D3 deficiency per se and not merely a consequence of
cell cycle deregulation. A combined knockdown ofCcnd3 and
Rb1, which rescued cell cycle progression into S phase, failed
to normalize virus production. Infection by influenza A virus
triggered redistribution of cyclin D3 from the nucleus to the
cytoplasm, followed by its proteasomal degradation. When
overexpressed in HEK 293T cells, cyclin D3 impaired binding
of M2 with M1, which is essential for proper assembly of
progeny virions, lending further support to its role as a puta-
tive restriction factor. Our study describes the identification
and characterization of cyclin D3 as a novel interactor of
influenza A virus M2 protein. We hypothesize that competi-
tive inhibition of M1-M2 interaction by cyclin D3 impairs
infectious virion formation and results in attenuated virus
production. In addition, we provide mechanistic insights into
the dynamic interplay of influenza virus with the host cell
cycle machinery during infection.
The threat of influenza infection is felt globally, and the dis-
ease leads to an estimated 3–5million cases of severe illness and
about 250,000–500,000 deaths each year (1). Although the
strategy of antagonizing influenza infection through vaccina-
tion has been partially successful, the necessity for effective
antiviral agents is underscored by the toxic side effects of cur-
rently available drugs and the emergence of drug-resistant vari-
ants (2–4). Influenza viruses, like any other viruses, are obligate
intracellular pathogens that exploit the host cellular machinery
to replicate. The identification of cellularmechanisms required
for the virus life cycle not only sheds light on its trafficking
characteristics but also provides strategies for interfering with
host factors as an alternative approach to inhibit viral infection.
Elucidating host-pathogen interactions as an unbiased
approach to gain insights into disease pathogenesis has
received ample attention. Various functional assay systems
have been used for screening host factors involved in the influ-
enza virus replication cycle thus far. From RNA interference
(RNAi)-based genome-wide screening strategies in Drosophila
(5) andmammalian systems (6–9) to other approaches, includ-
ing proteomics (10, 11), yeast two-hybrid (Y2H)3 analyses (7,
12), andmicroarrays (7, 13–15), extensive information has been
acquired. Multiple cellular networks have been implicated in
influenza virus replication through either direct protein-pro-
tein interactions (10, 16) or signaling pathways (17). Although
these strategies unveiled hundreds of genes important for the
virus life cycle, their functional relevance and molecular mech-
anisms are still poorly understood. Among others approaches,
effort has been invested to dissect how the cellular interactors
of viral ribonucleoprotein complexes regulate the replication
and transcription of influenza virus (18). Host interactors of the
non-structural protein 1 (NS1), amultifunctional proteinmod-
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ulating several aspects of the virus replication cycle with a
major role in inhibiting interferonmediated immune response,
have also been extensively studied (16). However, little atten-
tion has been drawn to identifying cellular factors associated
with the viral matrix protein 2 (M2).
We reasoned that the integralmembrane proteins of the viral
envelope would interact with cellular factors at various stages:
endosomal fusion and release of the genetic material during
entry, transport from endoplasmic reticulum to the plasma
membrane, and assembly and budding of nascent virions.M2 is
a minor protein of the viral envelope that forms a homote-
tramer in its native state (19, 20). Interestingly, M2 possesses
the longest C-terminal tail among the three viral envelope pro-
teins, namely hemagglutinin (HA), neuraminidase, andM2. It is
an ion channel that was initially discovered as the target of the
antiviral drug amantadine and facilitates diffusion of protons to
the interior of the endosomally entrapped virus (21). Low pH
induces a conformational change in HA and subsequently trig-
gers fusion with the endosomal membrane during virus entry
(22).M2 is a 97-residue single-passmembrane protein that dis-
plays considerable pleiotropism. It determines the filamentous
morphology of some viral strains through binding to choles-
terol (23–25). The cytoplasmic tail (CT) of M2 interacts with
M1 at the site of virus budding for efficient packaging of virus
particles (26, 27). Rossman et al. (28) reported a role of M2-CT
in mediating cholesterol-dependent alteration in membrane
curvature at the neck of budding virions, leading to host ESCRT
pathway-independent membrane scission.
Altogether, these studies provide evidence that influenza
M2, especially the CT domain, plays a critical role in multiple
steps of the virus life cycle. Hence, the identification of cellular
interactors of M2 would provide mechanistic insights into
influenza pathogenesis and possibilities for development of
novel strategies to interfere with multiple steps of the infection
process. By usingM2-CT as bait, we screened a humanplacenta
complementary DNA (cDNA) library to identify host proteins
that either facilitate or restrict viral infection. Cyclin D3, a key
regulator of cell cycle G0/G1 phase progression, was uncovered
as a novel host factor interacting with M2-CT. The physical
interaction between M2 and cyclin D3 was confirmed in virus-
infected cells. Influenza A virus (IAV) infection resulted in host
cell cycle arrest in G0/G1 phase, which was accompanied by
cyclin D3 relocalization and degradation. Using a combination
of small interfering RNA (siRNA)-mediated genetic analyses
wefurthershowedthatcyclinD3restricts IAVproduction, inde-
pendent of its role in the cell cycle. The restriction of cyclin D3
on IAV life cycle did not impair viral protein synthesis but inter-
fered with M1-M2 binding, which may result in defective
assembly and release of progeny virions. The role of cyclinD3 in
the context of influenza infection has not been described pre-
viously.More interestingly, our results suggest a novel function
of cyclin D3 that is beyond its classical function in cell cycle
regulation.
Results
Identification of Cyclin D3 as M2-CT-binding Protein—The
IAVM2 ion channel protein is a multifunctional protein with a
highly conserved sequence among influenza A virus isolates
that approaches 95% identity in some regions (29, 30). Among
the three viral envelope proteins, M2 possesses the longest CT
with a high probability of interactions with the cellularmachin-
ery at various steps of the virus life cycle. These include fusion,
intracellular trafficking through the secretory pathway (31),
and virus assembly and budding at the plasma membrane (24,
32). It is of considerable interest to identify intracellular inter-
actors of M2-CT, not only to elucidate cellular components
that are exploited by influenza, but also to understand host
defenses involved in restricting the virus life cycle. To this end,
a random-primed cDNA library from human placenta was
screened by Y2H using the IAV M2-CT as bait (Fig. 1A). The
screening revealed human cyclin D3 (GenBankTM accession
number NM_001760.2) as one of the most prominent interac-
tors of M2-CT, as summarized in Table 1. Sequence alignment
of the positive clones pointed to amino acid residues 138–251
as the minimal interacting domain for M2-CT (Fig. 1B). The
M2-binding domain on cyclin D3 is largely outside of its cyclin
box,which is responsible for binding to and activation of cyclin-
dependent kinases (33, 34) and also the region in which the
greatest homology occurs among the D-type cyclins (35). This
finding, together with the absence of other cyclins among pos-
itive clones, suggests a certain degree of specificity of the inter-
action, which was tested in the next series of experiments.
Cyclin D forms a complex with and functions as a regulatory
subunit of cyclin-dependent kinases 4 and 6 (CDK2 and -4),
whose activity is required in the cell cycle early G1 phase (36).
There are three early G1 phase D-type cyclins (D1, D2, andD3),
which are functionally related with tissue-specific expression
profiles (37–43). Our results from Y2H screening indicate that
only cyclin D3, and not the other two D-type cyclins, interacts
withM2-CT.We first checked the specificity of this interaction
in human A549 lung epithelial cells. GST-M2-CT fusion pro-
teinwas purified and incubatedwithwild-type cell lysate to pull
down endogenous D-type cyclins. Cyclin D3 bound specifically
to GST-M2-CT and not to either GST or beads (Fig. 1C). Alto-
gether, these results confirm that cyclin D3 binds to the IAV
M2-CT.
To examine the intracellular association of M2-CT with
cyclin D3 during the IAV life cycle, co-immunoprecipitation
experiments were performed from virus-infected cells. HEK
293T cells were transiently transfected with a plasmid
encoding FLAG-tagged cyclin D3 (cyclin D3-FLAG) and
infected with influenza A/WSN/33 virus. Cell lysates were
immunoprecipitated with anti-FLAG antibody and immu-
noblotted with anti-M2 antibody. As shown in Fig. 1D (lane
1), M2 was found to co-purify with cyclin D3, demonstrating
their physical interaction during virus infection, either
directly or through a common interactor. No interaction was
observed in control samples, where cells were either mock-
transfected and immunoprecipitated with anti-FLAG anti-
body (Fig. 1D, lane 2) or transfected with cyclin D3-FLAG
and immunoprecipitated with isotype control antibody (Fig.
1D, lane 3). These data validate cyclin D3 as a bona fide
interactor of influenza M2, corroborating our results from
the Y2H screening.
The specificity of interaction between cyclin D3 andM2 was
tested using a panel of exogenously expressed cyclins (cyclin
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D1, D2, D3, and E1). Although M2 appears to interact with
other cyclins to some degree when they are overexpressed, we
consistently found that it has the strongest interaction with
cyclin D3 (Fig. 1E).
IAV Infection Induces CyclinD3Relocalization andTargets It
for Proteasomal Degradation—To understand the functional
relevance of cyclin D3-M2 interaction in virus-infected cells,
we tested their subcellular distribution through immunofluo-
rescence imaging. To achieve unbiased analysis, A549 cells
were infected with influenza A/WSN/33 virus at anMOI of 0.5
to have a mixed population of infected and uninfected cells in
the same sample. Cells were fixed at 24 h postinfection (p.i.) and
stained for cyclin D3 and M2 proteins. In uninfected cells,
cyclin D3 resides both in the nucleus and in the cytoplasmwith
only the nuclear CDK4/6-cyclin D3 complex displaying retino-
blastoma (Rb)-directed kinase activity (44). Interestingly, upon
virus infection, amuchweaker cyclin D3 signal was observed in
the nuclei of infected cells compared with control cells, as
revealed byM2 staining. These results suggest that cyclin D3 is
redistributed from the nucleus to the cytosol as a response to
infection (Fig. 2A, top panels). The effect of M2 protein on
cyclin D3 relocalization was recapitulated in analogous experi-
ments using A549 cells expressing M2 protein alone (Fig. 2A,
bottom panels), which resulted in the apparent reduction of
cyclinD3 from thenucleus, similar to the phenotype induced by
viral infection.
To address the reduction of cyclin D3 from the nucleus upon
virus infection, we fractionated both control and infected cells
into cytosol and nuclear material to measure cyclin D3 levels.
Cytoplasm- and nucleus-enriched extracts were prepared from
A/WSN/33-infected (MOI of 2 to achieve a more homogene-
ous infection of the cell culture) and uninfected A549 cells.
Lamin B1 and GAPDH were used as markers to verify clear
separation of nuclear and cytoplasmic fractions. Total intracel-
lular level of cyclinD3 in virus-infected cells decreased to60%
of that observed in mock-infected cells (Fig. 2, B and C, top).
Densitometric analysis indicates that 10% of total cyclin D3was
found in the nucleus of uninfected cells. This is very likely an
underestimation because cyclin D3, being soluble, would leak
from the nuclear into the cytoplasmic fraction during the
experimental procedures. The percentage of nuclear cyclin D3
dropped to 4% at 8 h p.i. (Fig. 2C, bottom), indicating trans-
FIGURE 1. Identification of cyclin D3 as a specific cellular interactor ofM2
influenza protein.A, schematic representation of structuralmotifs in theM2
protein with the enlarged sequence of the CT used as the bait for the yeast
two-hybrid screen. ED, ectodomain; TM, transmembrane domain. B, sche-
matic representation of cyclin D3. The retinoblastoma (Rb)-binding LXCXE
motif; the proline (P), glutamic acid (E), serine (S), and threonine (T)-rich PEST
domain, which has been postulated to be involved in the rapid degradation
of unstable proteins; and the M2-minimal interacting domain are shown.
Numbers, amino acid positions. C, GST pull-down assay using whole cell
lysates from A549 cells. Samples were incubated with either naked beads,
GST control (GST), or GST fused to the cytoplasmic tail of A/WSN/33 virus M2
protein (GST-M2-CT) and analyzed by immunoblotting with anti-cyclin D3
antibodies after pull-down. Results are representative of three and two inde-
pendent experiments for cyclin D3 and cyclin D1 pull-down, respectively.
Dotted lines, sliced lanes from the samegel. GSTprotein inputwas revealedby
Coomassie Blue staining. D, co-immunoprecipitation of M2 with cyclin D3.
HEK 293T cells infected with A/WSN/33 virus at an MOI of 2 were lysed at 6 h
after infection and subjected to immunoprecipitation (IP) with anti-FLAG or
isotype control antibodies. Cell lysates or pellets following immunoprecipita-
tion were analyzed by immunoblotting (IB) using the indicated antibodies.
Transfection and infection conditions are shown above the blots. Results are
representative of three independent experiments. E, HEK 293T cells were
transfectedwith plasmids encodingMyc-tagged cyclins 48 hbefore infection
with A/WSN/33 virus at anMOI of 2. Cells were lysed at 6 h after infection and
subjected to immunoprecipitation with anti-Myc or isotype control antibod-
ies. Cell lysates or pellets following immunoprecipitation were analyzed by
immunoblotting using the indicated antibodies. Transfection and infection
conditions are shownabove theblots.M2was found to interactwith all cyclins
tested, albeit to different intensities. Results are representative of three inde-
pendent experiments.QuantitationofM2pull-down levelswasperformedby
densitometric analysis of immunoblots. M2 level was normalized to the
respective immunoprecipitated Myc-tagged protein level in each condition.
The degree of association of M2with cyclin D1was around 50% that of cyclin
D3when the sameamountof cyclinswas immunoprecipitated.Weakbinding
of M2 to cyclin D2 and cyclin E1, which plays a role in the cell cycle clock one
step later than D-type cyclins and is required for cell cycle G1/S transition in
association with cyclin-dependent kinase 2 (CDK2), was also observed in our
experiments. The bar graph shows themean S.D. (error bars) of three inde-
pendent experiments. **, p 0.005; ***, p 0.0001 by one-way ANOVA.
TABLE 1
Yeast two-hybrid screen identifies/predicts cyclin D3-M2-CT
interaction
Characteristic Value or description
Bait M2 cytoplasmic tail (amino acids 44–97)
Library Random-primed human placenta cDNA
No. of interactions tested 63.89 million
Prey Cyclin D3
No. of positive clones 42
Confidence scorea A
Minimal interacting domain Amino acids 138–251
a Predicted biological score (from A to E, highest to lowest), a statistical confi-
dence score assigned to each interaction by Hybrigenics.
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location of cyclin D3 from the nucleus to the cytoplasm in
virus-infected cells. This significant (60%) reduction of
nuclear cyclin D3 detected through biochemical measurement
confirmed our immunofluorescence data on its subcellular
relocalization.
We further verified colocalization of cyclin D3 with that of
M2 through infection of A/WSN/33 in cyclin D3-expressing
cells. Because at 24 h p.i. most of cyclin D3 is degraded, we
selected an earlier time point and treated mock- and virus-
infected cells with MG-132 to increase the signal strength of
cyclinD3. Indeed, at 15 h p.i., we could capture colocalization of
influenza M2 and cyclin D3 along the secretory pathway (Fig.
2D). Most of cyclin D3 appeared in the cytosolic fraction under
these conditions. Interaction of cyclin D3 with M2, combined
with its enrichment in the cytosol uponM2 expression strongly
suggests that this association must occur in the cytosol, either
FIGURE 2. Influenza A virus infection drives cyclin D3 redistribution from nucleus to cytoplasm. A, cyclin D3 subcellular distribution is altered upon M2
expression. A549 cells were infected with A/WSN/33 virus at an MOI of 0.5 or transfected with a plasmid expressing M2 protein. At 24 h after infection or
transfection, cells were fixed for immunofluorescence staining. The subcellular localization of cyclin D3 (red) and M2 (green) was visualized through immuno-
staining with specific antibodies and analyzed by confocal microscopy. Yellow arrowheads, nuclei of uninfected or non-transfected cells. White arrows,
virus-infected or M2-expressing cells. Bar, 20m. B, cyclin D3 translocates from nucleus to cytoplasm after viral infection. Left, cytoplasmic (C) and nuclear (N)
fractions of virus-infected (MOI of 2) or uninfected cells were prepared from A549 cells 8 h after infection. Lysates were resolved by SDS-PAGE and immuno-
blotted with anti-cyclin D3. Levels of lamin B1 and GAPDHwere used as controls to verify clean separation of nuclear and cytoplasmic fractions, respectively.
Results are representativeof three independent experiments.C, quantitationof cyclinD3 levelswasperformedbydensitometric analysis of immunoblots.Data
are presented as percentage of cyclin D3 remaining in the nucleus as a fraction of the total. Both mock- and virus-infected groups were normalized to total
cyclin D3 levels in uninfected cells. The bar graph shows themean S.D. (error bars) of three independent experiments. **, p 0.005 by unpaired Student’s t
test. D, colocalization of cyclin D3 and M2 in virus-infected cells. A549 cells expressing cyclin D3 were infected with A/WSN/33 virus at an MOI of 2 in the
presence of MG-132 to block protein degradation through proteasome and fixed at 15 h postinfection. The subcellular localization of cyclin D3 (red) and M2
(green) was visualized through immunostaining with specific antibodies and analyzed by confocal microscopy. Bar, 20 m.
Restriction of Influenza Infection by Cyclin D3
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directly or as a complex presumably en route to assembly and
release of intact progeny virions.
The induction of D-type cyclins is growth factor-dependent,
and both mRNAs and proteins exhibit moderate oscillations in
continuously proliferating cell populations (37, 38, 45–48).
Given the decrease in total intracellular cyclin D3 levels
observed in virus-infected cells, we next addressed whether
influenza virusmodulates cyclinD3protein levels in addition to
altering its subcellular localization. The expression profiles of
cyclin D3 and another cell cycle G1 phase regulator, cyclin E,
were measured through immunoblotting. Cyclin D3 was dra-
matically down-regulated by IAV infection to almost undetect-
able levels compared with uninfected cells at 24 h p.i. (Fig. 3A,
top). A time course analysis revealed that the steady-state levels
of cyclin D3 started declining at 6 h p.i. and decreased by50%
at 9 h p.i. (Fig. 3A, bottom). Cyclin E, which is activated at the
late stage of cell cycle G1 phase to facilitate G1/S transition,
displayed only amoderate reduction under identical conditions
(Fig. 3A), contrary to the finding by He et al. (49), where cyclin
E was vastly down-regulated by IAV infection. However, no
quantitative analysis was provided in their study, preventing us
from comparing the reduction level. It is worth noting that
cyclin E exists as multiple proteins ranging in size from Mr
35,000 to 50,000 in tumor cell lines, as illustrated by others (see
also Fig. 3A) (50, 51). However, only one band size of cyclin E
was shown in their study, although the same cell type was used.
The differential regulation of cyclin D3 and cyclin E indicates
that IAV infection specifically deregulates components in the
early G1 phase (G0/G1 phase) of the cell cycle machinery.
To further investigate the mechanism of virus-induced
cyclin D3 down-regulation, we determined the involvement of
the proteasomal degradation pathway in this process. Cells
were infected with A/WSN/33 virus in the absence or presence
of proteasome inhibitors, MG-101 or MG-132, and tested for
cyclin D3 levels. MG-101, also known as calpain inhibitor I,
inhibits both proteasome and calpain activities (52). Calpain is a
calcium-dependent protease that produces limited proteolysis
of its substrates. Resulting fragments are further degraded by
other proteolytic pathways, including proteasome (52). Calpain
has been reported to regulate cyclin D1 at the posttranscrip-
tional level (53). MG-132 is a proteasome inhibitor that pre-
vents degradation of ubiquitin-conjugated proteins (54). Unin-
fected cells were treated with the same drugs to control for the
baseline oscillation of cyclin D3 levels. Proteasome inhibition
did not affect cyclinD3 abundance in uninfected cells; however,
blocking proteasome activity led to a significant stabilization of
cyclin D3 in virus-infected cells. MG-101 and MG-132 treat-
ments blocked cyclin D3 degradation by 50 and 60%,
respectively, compared with the vehicle control (DMSO)-
treated group, as measured by densitometric analysis of immu-
noblots (Fig. 3B). Thus, an obvious rescue of cyclin D3 was
observed after one round of infection (9 h p.i.) through the use
of proteasome inhibitors. The regulation of other cell cycle
moderators was also investigated. Although viral infection also
resulted in cyclin D1, CDK4, and CDK6 down-regulation on
protein level (Fig. 4A), the level of down-regulation is not as
robust as that of cyclin D3, and their protein levels could not be
rescued by protease and calpain inhibitor when compared with
cyclin D3 (Fig. 4B). These findings suggest that IAV posts a
cyclin D3-specific effect during infection.
Our data indicate that IAV infection results in reduced cyclin
D3 levels in the nucleus of virus-infected cells. This phenotype
is triggered by translocation of nuclear cyclin D3 into the cyto-
plasm, where IAV facilitates proteasomal degradation of cyto-
plasmic cyclin D3.
Influenza A/WSN/33 Virus Infection Arrests Cell Cycle in G1
Phase—The principal role of the D-type cyclins is to act as
growth factor sensors, converting environmental signals into
FIGURE 3. IAV infectiondown-regulates protein levels of cyclinD3 throughproteasome-mediateddegradation.A, IAV infection reduces protein level of
cyclin D3 but not cyclin E. A549 cells were infected with A/WSN/33 virus at an MOI of 2. Top, cells were lysed at specified time points, subjected to SDS-PAGE,
and visualized by Western blotting. Results are representative of three independent experiments. Bottom, densitometric quantitation of cyclin D3 and cyclin
Enormalized toGAPDH. Linegraphs representmeanS.D. (error bars) from three independent experiments. *,p0.05; **,p0.01; ***,p0.001 versusmock
at each time point by two-way ANOVA. B, cyclin D3 is targeted for proteolysis after viral infection. Top, A549 cells, either mock- or virus-infected, were treated
with proteasome inhibitors MG-101 or MG-132 at the initiation of viral infection. Whole cell lysates were extracted at 9 h after infection for detection of cyclin
D3 protein levels. Bottom, densitometric analysis of immunoblots for cyclin D3 levels (normalized to GAPDH). Results are representative of three independent
experiments. The bar graph shows the mean S.D. from three independent experiments. *, p 0.05 by unpaired Student’s t test.
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fuel for the cell cycle engine. The interaction between cyclin D3
and M2-CT during the viral life cycle implies a potential regu-
lation of host cell cycle by IAV. This is supported by our obser-
vation that cyclin D3 is actively removed from the nucleus and
degraded by the proteasome in virus-infected cells. To address
whether the cell cycle is compromised, a quantitative profiling
of cell cycle kinetics was performed on virus-infected A549
cells. Using an asynchronously growing cell population, we
found that virus-infected cells accumulated at G1 phase when
compared with the uninfected group (data not shown). To
reduce variability due to a mixed population of cells in differ-
ential phases of the cell cycle, we first synchronized thembefore
infection in G1 using lovastatin, a fungal metabolite shown to
affect cell cycle distribution in a reversible manner (55). Cells
were released from the lovastatin block and stimulated with
mevalonate at the time of infection to trigger progression into
later cell cycle stages. BrdU incorporation and DNA content
staining showed that virus infection brought about a cell cycle
arrest at 9 h p.i. (Fig. 5A). The overlay of cell cycle patterns of
virus-infected and uninfected cells indicates that infection
decreased the peaks representing cells in S and G2/M phases
(Fig. 5B). The percentages of cells in G1 phase exhibited a pro-
gressive, time-dependent drop from 83.0 2.1 to 80.1 0.9%
and subsequently 45.7 2.8% (at 0, 9, and 24 h p.i., respectively;
means S.D. of three experiments) in the mock-infected sam-
ples. This reduction reflects progression of cells through G1
phase, followed by entry into the later stages of the cell cycle. In
contrast, cells infected byA/WSN/33 virus remained inG1with
FIGURE 4. IAV specifically targets cyclin D3 for proteasomal degradation. A, IAV infection reduces protein level of cyclin D1, CDK4, and CDK6. A549 cells
were infectedwith A/WSN/33 virus at anMOI of 2. Cells were lysed at specified time points, subjected to SDS-PAGE, and visualized byWestern blotting. Results
are representative of three independent experiments. Line graphs represent mean  S.D. (error bars) of band intensity obtained through densitometric
quantitation from three independent experiments. **, p 0.01; ***, p 0.001 versus mock at each time point by two-way ANOVA. B, cyclin D3 is specifically
targeted for proteolysis after viral infection. Virus-infected (MOI of 2) A549 cells were treatedwith proteasome inhibitorsMG-101 orMG-132 at the initiation of
viral infection. Whole cell lysates were extracted at 24 h p.i. for detection of the protein levels of cell cycle regulators. Results are representative of three
independent experiments. The bar graph shows the mean S.D. of band intensity obtained through densitometric analysis from three independent exper-
iments (normalized to GAPDH). *, p 0.05; **, p 0.005; ***, p 0.001 by unpaired Student’s t test.
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FIGURE 5. IAV leads to cell cycle arrest in G0/G1. A, IAV infection altered the cell cycle progression of A549 cells presynchronized in G1 phase. A549 cells were
treated with lovastatin 22 h before infection with A/WSN/33 virus to synchronize them in G0/G1 phase. Cells were released from drug treatment at the start of
infection (MOI 2), which lasted for the indicated timeperiods, and incubatedwith 10MBrdU for cell cycle analysis 1 h before harvesting. B, cell cycle pattern
ofmock- andvirus-infected cell populations at 24hafter infection thatwerepresynchronized inG0/G1phasewith lovastatin. Results are representativeof three
independent experiments. C, percentage of cells in G0/G1 phase after lovastatin treatment in mock- or virus-infected cells. Line graph illustrates mean S.D.
(error bars) of three independent experiments. ***, p 0.001 versusmock at each time point by two-way ANOVA.D, IAV infection arrested cells in G0/G1 phase
in an A549 population presynchronized in G2/M phase. CDK1 inhibitor RO-3306 was used to accumulate A549 cells in G2/M for 18 h. Immediately after drug
removal, cells were infected with A/WSN/33 virus (MOI 2) and treated as above for cell cycle analysis following BrdU incorporation. E, cell cycle pattern of
mock- and virus-infected cell populations that were presynchronized in G2/M phase with RO-3306. Results are representative of three independent experi-
ments. F, percentage of cells in G0/G1 phase after RO-3306 treatment in mock- or virus-infected cells. The line graph illustrates mean S.D. of three indepen-
dent experiments. ***, p  0.001 versus mock at each time point by two-way ANOVA. Flow cytometry data were obtained with a BD LSRII flow cytometer.
Scattergrams are representative of three independent experiments. In A and D, scattergrams show DNA content staining versus BrdU incorporation of each
individual cell for cell cycle status determination. Boxed and circled areas define cell populations in each phase of the cell cycle indicated on the graph.
Restriction of Influenza Infection by Cyclin D3
5076 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 12•MARCH 24, 2017
 by guest on M
ay 5, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the percentage of cells in G1 phase hovering above 80% at all
time points (Fig. 5C). Our results demonstrate that IAV infec-
tion impairs progression of cell cycle through the G1/S
intersection.
To further prove that IAV infection induced cell cycle arrest
in G1 phase, we used a separate approach. Cells were preaccu-
mulated in G2/M phase by treatment with RO-3306, a CDK1
inhibitor (56). At 0 h p.i., both A/WSN/33-infected and control
samples had comparable percentages of cells in all phases of the
cell cycle (Fig. 5D). Similar to the result obtained with lovasta-
tin, the cell cycle pattern of virus-infected cells showed lower
peaks for both S and G2/M phases when compared with unin-
fected cells (Fig. 5E). Upon recovery of cells from drug restric-
tion, both uninfected and infected cells resumed division and
initiated a new round of cell cycle, displaying an increased per-
centage of cells representing G0/G1 phase at 9 h p.i.; only unin-
fected cells, however, progressed further into S phase. The per-
centage of cells in G0/G1 phase dropped from around 85 to 65%
in the control sample, whereas it remained constant in IAV-
infected cells (Fig. 5F). Collectively, these results indicate that
IAV infection perturbs normal cell cycle progression in human
cell lines and installs a block at G0/G1 phase.
D-type cyclins activate CDK4/6, which initiate phosphoryla-
tion of Rb at multiple sites. Hyperphosphorylated Rb (ppRb)
releases transcription factor E2F and leads to the activation and
transcription of cell cycle progression-responsive genes (38, 57,
58). To test whether IAV-induced cell cycle arrest was imposed
by Rb, the phosphorylation status of Rb was monitored. Phos-
phorylation on serine 780 (ppRb Ser-780) is specifically cata-
lyzed by the cyclin D-CDK4/6 complex but not cyclin E-CDK2
(59). Not surprisingly, IAV infection progressively resulted in
diminished levels of ppRb Ser-780 as a function of time (Fig.
6A). Furthermore, serine 807/811 phosphorylation on Rb
(ppRb Ser-807/811), which affects the S phase of the cell cycle
displayed a similar trend (60) (Fig. 6A), an observation consis-
tent with the virus-induced block at G0/G1 phase. In line with
the down-regulation of ppRb proteins, accumulation of hypo-
phosphorylated Rb (pRb) was observed (Fig. 6A).
FIGURE 6. IAV infection inhibits hyperphosphorylationof Rbanddown-regulatesCDK inhibitor p21WAF1/CIP1.A, A549 cellswere infectedwithA/WSN/33
virus at anMOI of 2. At the indicated time points, whole cell lysates were prepared from both infected and uninfected cells to determine the phosphorylation
status of Rb and levels of CDK inhibitor p21WAF1/CIP1. Results are representative of three independent experiments. Right, densitometric analyses of Rb and
p21WAF1/CIP1 levels were performed on immunoblots (normalized to GAPDH). Line graphs represent the mean  S.D. (error bars) of three independent
experiments. *, p 0.05; **, p 0.001 versusmock at each time point by two-way ANOVA. B, p21WAF1/CIP1 is targeted for proteolysis after viral infection. Left,
A549 cells, eithermock- or virus-infected, were treatedwith proteasome inhibitorMG-101 orMG-132 at the initiation of viral infection.Whole cell lysates were
extracted at 9 h after infection for detection of p21WAF1/CIP1 protein levels. Right, densitometric analysis of immunoblots for p21WAF1/CIP1 levels in cells treated
with different inhibitors (normalized to GAPDH). Results are representative of three independent experiments. The bar graph shows the mean S.D. from
three independent experiments. **, p 0.005; ***, p 0.0005 by unpaired Student’s t test.
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Inhibition of cell cycle can also occur through induction of
cyclin-dependent kinase inhibitors (CKIs). P21WAF1/CIP1 is a
“universal” CKI that inhibits both cyclin and CDK subunits to
install a p53-dependent G1 phase arrest (61). Interestingly,
upon infection, p21WAF1/CIP1 was down-regulated through
proteasomal degradation, indicating that IAV-induced G0/G1
arrest was not mediated through the p53/p21WAF1/CIP1 path-
way (Fig. 6, A and B). Expression levels of p16 from the INK4
family of CKI, which specifically inhibits the catalytic subunits
of CDK4 and CDK6, were also measured. No increase in
p16INK4A was observed even after prolonged infection time
(data not shown).
From the results described above, we conclude that IAV
infection down-regulates cyclin D3 levels, which in turn inhib-
itsCDK4/6activationandultimately results inreducedRbphos-
phorylation. Consequently, pRb sequesters the transcription
factor E2F, which prevents cell cycle entry into S phase (58).
Cyclin D3 Negatively Modulates Influenza Virus Infection—
To establish a functional relevance for cyclin D3 in IAV patho-
genesis, we studied the effect of Ccnd3 knockdown on virus
replication. To avoid off-target effects imposed by the use of
siRNA pools, we used an individual siRNA duplex from the
published literature (CCND3 #1) for generating a knockdown
(62). siRNA CCND3 #1 effectively reduced endogenous cyclin
D3 expression levels by 90% at 72 h post-transfection, com-
pared with a nonspecific control siRNA (nontargeting (NT))
(Fig. 7A). Control (NT siRNA-treated) and cyclin D3-deficient
cells were infected with A/WSN/33 at an MOI of 0.01 to allow
multiple rounds of infection. Viral titers obtained from cyclin
D3-deficient cells were at least 10-fold greater than those from
control cells (Fig. 7B, left). Because cyclin D3-M2 interaction
was identified using avian M2-CT, we measured the effect of
Ccnd3 knockdown on the replication of highly pathogenic
H5N1 avian influenza virus and observed a more 10-fold
higher progeny virus production in cyclin D3-deficient cells
when compared with control group at 24 h p.i. (Fig. 7B, right).
The difference in production of H5N1 virus was less significant
at 48 h p.i. (2.5-fold), most likely due to the cytopathic effect
of H5N1 virus in a limited cell culture system.
To differentiate whether the increased progeny virus titer
was intrinsic to the absence of cyclin D3 protein or a conse-
quence of cell cycle arrest induced by cyclin D3 silencing, we
next used combinations of siRNAs targeting various steps in the
cell cycle to modulate its progression. Concomitant knock-
down of Ccnd3 and Rb1 rescued cells from the G0/G1 phase
block imposed by cyclin D3 deficiency, allowing us to measure
the effect of cyclinD3 alone on virus replication. In addition, we
included aCcne1 knockdown, which induced cell cycle arrest at
the G1/S interface without affecting cyclin D3 levels. To gain
further confidence in the specificity of the cyclin D3 siRNA, we
included a second siRNAduplex specific for cyclinD3 (CCND3
#2). Both individual siRNAs and siRNA combinations resulted
in significant reduction of the desired gene expressions (Fig.
7C). In the control siRNA-treated cell population, around 55%
of cells were found inG0/G1 phase of the cell cycle. As expected,
knockdown of Ccnd3 alone arrested cell cycle progression in
A549 cells with 65% (CCND3 #1) or 70% (CCDN3 #2) of
cells in G0/G1 phase when compared with cells treated withNT
siRNA. A concomitant Ccnd3/Rb1 knockdown rescued cell
cycle progression into S phase. Knockdown of Ccne1 expres-
sion in A549 cells induced amore robust cell cycle G0/G1 phase
accumulation than Ccnd3 knockdown with 80% cells in
G0/G1 phase (Fig. 7D). For all siRNA-mediated knockdowns,
cells were subjected to infection with A/WSN/33 virus at an
MOI of 0.01 at 72 h post-transfection for progeny virus produc-
tion. Ccnd3 knockdown with the two individual siRNA
duplexes increased progeny virus titers by approximately 1 log.
Despite the rescue in cell cycle progression, a double knock-
down of Ccnd3/Rb1 did not normalize virus production when
compared with NT siRNA-treated cells. A 5-fold difference in
viral titers persisted between control cells and those that har-
bored a double knockdown in Ccnd3/Rb1. Virus titers from
cells with Ccne1 knockdown were comparable with those from
Ccnd3/Rb1 double knockdown (Fig. 7E, left).
To study whether the inhibitory role of cyclin D3 on viral
replication is also applicable to the other IAV strains, two clin-
ical isolates were tested. At both 24 and 48 h p.i., equivalent or
higher virus titers for influenza A/HK/1/68 (H3N2) and A/HK/
54/98 (H1N1) viruses confirmed our results with A/WSN/33
(Fig. 7E,middle and right panels).
To examine the distribution of D-type cyclins in the context
of natural infection, we determined their expression in the
human airway, in particular human bronchial epithelial cells
(HBECs) and pneumocytes. Although cyclin D3 mRNA was
expressed at lower levels compared with the other two D-type
cyclins in both cell types (Fig. 8A), comparable protein amounts
of cyclin D3 were detected in A549, HBEC, and pneumocytes
(Fig. 8B). Cyclin D2 expression could be detected in the two
primary cells but not inA549 (Fig. 8B). Collectively, cyclinD3 is
expressed in tissues along the natural infection route of IAV. To
validate its functional relevance in these cells, we performed a
knockdown of cyclin D3 in HBECs to study its effect on influ-
enza virus production. As observed with A549 cells, cyclin D3
deficiency in HBEC resulted in10-fold increase in viral titers,
supporting our conclusions from experiments performed in
actively dividing cells (Fig. 8, C and D).
Cyclin D3 Inhibits M2 andM1 Interaction but Not Viral Pro-
tein Synthesis—To understand the mode of cyclin D3-imposed
restriction of IAV production, we first measured whether viral
protein synthesis was affected by cyclin D3. To separate the
effect of cyclin D3 deficiency from cell cycle arrest, we used
the Ccnd3/Rb1 double knockdown. Multiple time points were
selected to measure viral protein synthesis within a single cycle
of infection. Knockdown cells did not display enhanced viral
protein synthesis compared with control cells (Fig. 9), suggest-
ing that the effect of cyclin D3 on IAV infection probably
occurred at a later step after viral protein translation.
The biogenesis of viral particles involves proper packaging
and assembly of viral proteins andRNA to form intact virions at
discrete budding sites.M2 is amultifunctional protein; its cyto-
solic tail interacts with M1, promoting the recruitment of viral
internal proteins and vRNA to the plasma membrane for effi-
cient virus assembly (27). We postulated that binding of cyclin
D3 to M2-CT might affect M1-M2 interaction, resulting in
attenuated virus release due to either (i) production of defective
virus particles due to improper packaging or (ii) incomplete
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assembly of virions and hence generation of fewer particles. To
test this hypothesis, HEK 293T cells were co-transfected with
cyclin D3, M1, and M2. Cells expressing M1 and M2 without
exogenous cyclin D3 were used as control. For both conditions,
M1-M2 binding was detected through co-immunoprecipita-
tion followed by immunoblotting (Fig. 10A, left, lane 1). Upon
FIGURE 7. Cyclin D3 negatively modulates influenza virus infection. A, analysis of siRNA-mediated gene knockdown efficiency. Whole cell lysates were
prepared fromA549 cells 72 h after the designated siRNA treatment. Western blotting was used to determine the expression levels of cyclin D3 and cyclin D1.
Results are representative of three independent experiments. B, Ccnd3 knockdown in A549 cells facilitates both low pathogenic and highly pathogenic IAV
infection. NTor cyclinD3 (CCND3#1 andCCND3#2) siRNA-treated cellswere infectedwith viruses at anMOI of 0.01 formulticycle infection. Progeny virus titers
in cell culture supernatants were determined through a plaque assay. The bar graphs depict themean S.D. (error bars) of three independent experiments. *,
p 0.05; **, p 0.01; ***, p 0.0001 versus control (NT) siRNA at each time point by unpaired Student’s t test. C, analysis of siRNA-mediated gene knockdown
efficiency. Lysateswereprepared fromA549 cells treatedwith the indicated siRNAs 72hpost-transfection. The expression levels of Rb, cyclin E, cyclinD3, cyclin
D1, and GAPDH proteins were determined by Western blotting. Results are representative of three independent experiments. D, cell cycle pattern of
siRNA-treated cells. A549 cells were fixed in 70% ethanol 72 h after siRNA treatment. The cell cycle pattern of each group was quantitated through BrdU
incorporation and 7-aminoactinomycin D DNA content staining. Data were obtainedwith a BD LSRII flow cytometer and presented as the percentage of total
cells in each phase. The bar graph shows the mean  S.D. of three independent experiments. **, p  0.001; ***, p  0.0001 versus NT siRNA by unpaired
Student’s t test. E, cyclinD3depletion in A549 cells increases progeny virus titer in supernatant. A549 cells treatedwith the indicated siRNAswere infectedwith
influenzaA/WSN/33 (H1N1) virus, A/HK/1/68 (H3N2), or A/HK/54/98 (H1N1) virus at anMOI of 0.01. Cell culture supernatantswere collected at 24 and 48h after
infection, and virus titers were determined by a plaque assay on MDCK cells. The bar graphs show the mean S.D. of three independent experiments. *, p
0.05; **, p 0.01; ***, p 0.0005 versus NT siRNA by unpaired Student’s t test.
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overexpression of cyclin D3, the level of M1 that co-precip-
itated with M2 was significantly lower than the amount
obtained in the absence of cyclin D3 (Fig. 10A, left, lane 2).
Densitometric analysis revealed that a reduction of70% in
binding of M1 to M2 was observed when cyclin D3 was over-
expressed (Fig. 10A, right). An isotype control antibody used
in parallel did not bind to M1 (Fig. 10A, left, lane 3). Our
results demonstrate that (i) cyclin D3 does not affect viral
protein synthesis during IAV life cycle and (ii) interac-
tion between M1 and M2 is significantly attenuated in the
presence of cyclin D3. We propose that through competi-
tion with M1 for M2 binding, cyclin D3 restricts IAV produc-
tion either through reduced or defective progeny virion
formation.
FIGURE 8. Cyclin D3 is expressed along the human airway. A, total RNA extracted from HBECs and pneumocytes was reverse transcribed into cDNA for
Taqman probe-based quantitative PCR gene expression analysis. Shown is a graphical representation of themean absolute copy number of cyclin D1, D2, D3,
and E1 in HBECs and pneumocytes. B, whole cell lysates of A549 cells, HBECs, and pneumocytes were extracted to determine the protein levels of the
designated cyclins through Western blotting (top). Densitometric analyses of immunoblots for cyclin D1, D2, and D3 in different cell types are shown in the
bottom panel (normalized to GAPDH). C, analysis of siRNA-mediated gene knockdown efficiency in HBEC. Whole cell lysates were prepared from HBECs cells
72 h after the designated siRNA treatment. Western blottingwas used to determine the expression levels of cyclin D3.D, Ccnd3 knockdown in HBEC facilitates
IAVprogeny virus production.NTor cyclinD3 (CCND3#2) siRNA-treated cellswere infectedwith viruses at anMOIof 0.01 formulticycle infection. Progeny virus
titers in cell culture supernatants were determined through a plaque assay. The bar graphs depict the mean  S.D. (error bars) of three independent
experiments. *, p 0.05; **, p 0.01; ***, p 0.0001 versus control (NT) siRNA at each time point by unpaired Student’s t test.
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To test this hypothesis, cyclin D3-deficient cells and control
cells were infected with A/WSN/33 to measure plasma mem-
brane expression of viral M2 protein within one cycle of infec-
tion. As illustrated in Fig. 6C, more M2 was detected at the
plasma membrane in cyclin D3-deficient cells. This suggests
that without the blockage imposed by cyclin D3, a greater
amount of M2 could reach the cell surface and/or at a faster
pace, thus facilitating the recruitment of viral internal compo-
nents to the plasmamembrane for assembly and budding. This
trend could be observed at both time intervals, as summarized
in Fig. 10B. In addition, we could validate these results using
confocal imaging. Overexpression of cyclin D3 resulted in both
M1 and M2 being predominantly confined to the early secre-
tory network compared with control cells with endogenous
cyclin D3 levels, where a significant fraction of M2 appeared at
the plasma membrane (Fig. 10C). Interestingly, although the
absence of cyclin E1 (a weak interactor of M2), facilitates IAV
progeny virus production, this effect occurs through a different
mechanism because M2 surface expression remained unaf-
fected in cells depleted of cyclin E1 (data not shown).
Discussion
The search for the interactome of M2 protein of IAV in host
cells has been limited so far. Host proteins that M2 has been
shown to exploit include Na/K-ATPase, heat shock protein
40 (Hsp40), and p58IPK (inhibitor of protein kinase) (63–67). In
addition, the amphipathic helix located within the M2-CT
binds to cholesterol and alters the local membrane curvature at
the budding zone while providing a scaffold for M1 polymeri-
zation and filament elongation (68). Withdrawal of cholesterol
or disruption of the M2 amphipathic helix inhibits viral fila-
ment formation (25). We previously identified annexin A6 as a
novel interactor with the M2-CT, which impairs budding and
release of IAV at late stages of the virus life cycle (69). More
recently, M2 was found to interact with the ATG8/LC3 family
of ubiquitin-related proteins residing on the autophagosomal
membranes (70, 71). A highly conserved LC3-interacting
region inM2promoted binding and relocalization of LC3 to the
plasma membrane. This mechanism allowed subversion of
autophagy and facilitated inter-organism viral transmission by
enhancing the stability of progeny virions.
In the present study, we identified cyclin D3 as a novel inter-
actor of IAV-M2 and systematically studied its role in the con-
text of IAV infection. Being a key regulator of cell cycle progres-
sion, Ccnd3 knockdown by default leads to cell cycle G0/G1
phase arrest, providing a favorable environment for IAV repli-
cation. Our results indicate that cyclin D3 functions beyond its
role in cell cycle in the context of influenza infection. The
absence of cyclin D3 in combination with accumulation of cell
cycle in G1 phase appears to have an additive effect on IAV
progeny virus production, indicating that cyclin D3 deficiency
specifically facilitates influenza virus production independently
of the cell cycle. Instead, co-immunoprecipitationwithM2 sug-
gests that cyclin D3 impairs nascent virus production at a late
stage of the virus life cycle by interfering with M1-M2 binding
(Fig. 11). Our results illustrate yet anothermechanism that IAV
has evolved to counteract host defenses; cyclin D3 is redistrib-
uted from the nucleus to the cytoplasm, where it is targeted for
proteasomal degradation. Indeed, mislocalization and subse-
quent down-regulation of restriction factors is one of the recur-
ring mechanisms viruses have adopted to overcome host
defenses (72). The presence of M2 traps cyclin D3 in the cyto-
plasm through two possible mechanisms: (i) M2 interacts with
newly synthesized cyclin D3 and prevents it from translocating
into the nucleus, or (ii) cyclin D3 is retained by M2 in the cyto-
plasm after its nuclear export. A detailed mechanism of how
cyclin D3 is targeted to the proteasome complex and which
E3-ligase ubiquitylates it will be pursued in future investiga-
tions. Down-regulation of the cyclin D3 transcript was previ-
ously observed in H5N1-infected cells, but its implication had
not been addressed (73). Our study has expanded the repertoire
of IAV-M2 host interactors and proposes a novel function of
cyclin D3 in the life cycle of IAV.
Manipulation of the cell cycle machinery has been adopted
by many viruses as a common strategy. For instance, HIV-1
FIGURE 9.CyclinD3deficiencydoesnot affect viral protein synthesis. Top, A549 cellswith knockdownof the indicatedgeneswere infectedwithA/WSN/33
virus at an MOI of 2 to determine their effect on viral protein synthesis. Whole cell lysates were collected at 3, 6, 9, and 12 h after infection to monitor protein
levels. Lysateswere resolvedbySDS-PAGE, and levels of viral nucleoprotein,M1, andM2weredetermined throughWesternblotting. Results are representative
of three independent experiments. Bottom, densitometric analyses of immunoblots for each protein at 12 h p.i. (normalized to GAPDH). Results are shown as
the mean S.D. (error bars) of three independent experiments.
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accessory protein Vpr is reported to induce arrest in G2 by
activating protein phosphatase 2A,which acts onmitosis inhib-
itors Wee1 kinase and Cdc25 phosphatase (74). Similar to our
findings, some other viral proteins have been found to bind
members of the cyclin family. Persistent infection with borna
disease virus results in reduced G2 toM progression (75). Like-
wise, the nucleoprotein of SARS-CoV inhibits the activity of
CDK4 by binding to cyclin D, which blocks S phase progression
(76). Viral proteins associate with particular cell cycle compo-
nents, thereby deregulating the host cell cycle clock to alter the
environment for more efficient replication. It remains to be
determined whether M2-cyclin D3 interaction inhibits the
FIGURE 10. Cyclin D3 competes with M1 for M2 binding. A, cyclin D3 impairs interaction between viral M2 and M1 proteins. Left, HEK 293T cells were
co-transfected withM1-HA andM2-FLAG (lane 1) or with M1-HA andM2-FLAG alongwith cyclin D3-FLAG (lanes 2 and 3), as indicated above each blot. At 48 h
post-transfection, cell lysates were collected and subjected to immunoprecipitation using anti-M2 (lanes 1 and 2) or isotype control (lane 3) antibodies.
Precipitateswere analyzed throughWestern blotting to detectM1,M2, and cyclin D3 proteins. Right, densitometric analyses of immunoblots to quantitate the
amount of viral M1 protein co-immunoprecipitating with M2 with or without the expression of cyclin D3 (normalized to immunoprecipitated M2 amount).
Results are shown asmean S.D. (error bars) of three independent experiments. **, p 0.005 by unpaired Student’s t test. B, cyclin D3 hindersM2 cell surface
expression. Left, control and cyclinD3-deficient cellswere infectedwithA/WSN/33, andplasmamembrane expression of viralM2proteinwas detectedby flow
cytometry at 6 and 8 h after infection. Histograms are representative of three independent experiments. Gating indicates cell populations that are positive or
negative for plasma membrane expression of M2 protein. Right, statistical analysis of the percentage of cells that were positive for surface expression of M2.
Results are shown asmean S.D. of three independent experiments. **, p 0.005; ***, p 0.0001 by unpaired Student’s t test. C, overexpression of cyclin D3
sequestered viralM1 andM2protein to the secretory network. A549 cellswere overexpressedwith cyclinD3protein 24 hbefore infectionwithA/WSN/33 virus
at anMOI of 2. Cells were fixed at 10 h p.i. and immunostained with specific antibodies to reveal the subcellular localization of M1 (red) andM2 (green). Bar, 20
m.
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kinase activity of CDK4/6 after IAV infection. A cell cycle arrest
in G0/G1 by IAV infection was first reported by He et al. (49),
although this phenomenonwas not investigated inmechanistic
terms. The non-structural protein 1 (NS1) of IAV was later
discovered to interact with and inhibit the activity of the Ras
homolog gene family member A (RhoA), providing some
molecular insights into the mechanism of IAV-induced cell
cycle perturbation (77). The present study quantitatively dem-
onstrated that IAV infection imposes a specific G0/G1 arrest
and established cyclin D3 mislocalization and degradation fol-
lowing its interaction with M2 as the underlying molecular
correlate.
Co-evolution and adaptation of virus-host interactions is
best described as a zero sumbiological arms race. However, due
to high mutation rates, viruses such as influenza are well
equipped to rapidly evolve strategies to evade host restriction
factors. Consequently, in the case of IAV infection, the effect of
cyclin D3 is successfully antagonized by M2, which redirects
cyclin D3 from the nucleus to the cytosol followed by protea-
somal degradation, thereby granting an advantage to virus
production.
Our study provides important insights into the mechanism
through which cyclin D3 restricts IAV infection. We demon-
strated that the increase in progeny virus production upon
Ccnd3 knockdown was not a result of enhanced viral protein
synthesis in host cells. Instead, the inhibitory effect of cyclin D3
on IAV infection is due to its interaction with viral M2 protein,
as measured by competitive co-immunoprecipitation assays.
Wehypothesize that cyclinD3-M2 interaction eithermasks the
domain onM2mediating binding toM1 or has a higher affinity
than that betweenM1 andM2.Another possibility is that cyclin
D3-M2 interaction sequesters the amount of available M2.
Consequently, limitedM1-M2binding during the budding pro-
cess of IAV infection results in fewer progeny virions being
efficiently packaged and released from host cells. Several host
factors have been identified that interfere with the late stage of
the viral life cycle, amongwhich tetherin (also known as BST-2)
is the best characterized. In addition, interferon-stimulated
gene (ISG) products are a group of newly emerging host restric-
tion factors that can control viral, bacterial, and parasite infec-
tion, as exemplified by viperin and ISG15, to name a few (78–
81). The current study includes cyclin D3 in the family of IAV
budding inhibitors and provides insights into the dynamic
interplay between cyclin D3 and M2 during IAV infection.
Experimental Procedures
Yeast Two-hybrid Screening—Influenza A virus M2-CT
(A/Goose/Guangdong/1/96; GenBankTM accession number
81975894) was used as bait to screen for interactors from a
random-primed human placenta cDNA library, which contains
10million independent fragments. The cloning of bait and Y2H
screening were performed by Hybrigenics (Paris, France).
Briefly, M2-CT was fused with the LexA binding domain by
subcloning it into the pB27 vector. The L40GAL4 yeast strain
was then transformed with pM2-CT bait plasmid and mated
with Y187 yeast strain transformed by the prey library (82).
Clone selectionwas performed on leucine, tryptophan, and his-
tidine drop-outmedium, and 273 positive diploids were picked.
Identified prey fragments were then subjected to PCR and
sequencing. After going through filtration and being divided
into contigs, sequences were compared with the most recently
updated GenBankTM database by using BLASTN to decode
interactions. All interactions were assigned with computative
confidence scores to assess interaction reliability (83).
Cells and Viruses—Human alveolar basal epithelial (A549),
human embryonic kidney (HEK 293T), and Madin-Darby
canine kidney (MDCK) cells were purchased fromATCC. Dul-
becco’s modified Eagle’s medium (DMEM) (Invitrogen) sup-
plemented with 10% fetal bovine serum (FBS), 100 units/ml
penicillin, and 100 g/ml streptomycin (Invitrogen) was used
to culture and maintain all cell types used.
Influenza A virus strains A/WSN/33 (H1N1), A/HK/1/68
(H3N2), A/HK/54/98 (H1N1), and A/Vietnam/1203/2003
(H5N1) were propagated in MDCK cells supplemented with
0.3% bovine serum albumin (BSA) (Sigma-Aldrich) in the pres-
ence of 1 g/ml tosylphenylalanyl chloromethyl ketone
(TPCK)-treated trypsin (Thermo Scientific) and stored as virus
stocks at	80 °C until further use. Viral titers were obtained by
a plaque assay onMDCKcells. Briefly, serial 10-fold dilutions of
virus stocks were adsorbed onto a confluent monolayer of
MDCK cells for 1 h at 37 °C. Next, viral inoculums were
removed, and cells were washed twice with phosphate-buffered
saline (PBS), pH 7.4. Cells were then covered with 1% semisolid
agar in DMEM complemented with 0.3% BSA and 1 g/ml
FIGURE 11.Workingmodel of cyclinD3 function in the context of influenza virus budding. In normal cells, cyclin D3 displays nuclear localization, which is
essential for cell cycle regulation. During influenza A virus infection, cyclin D3 interacts with viral M2 protein. The cyclin D3-M2 interaction impairs binding of
M2 toM1, which is required for virus assembly and budding at the plasmamembrane. In the absence of cyclin D3, more infectious progeny virus particles are
released into the supernatant of virus-infected cells. Influenza virus, however, antagonizes cyclin D3 inhibition by (i) redistributing cyclin D3 between nucleus
and cytoplasm, which contributes to cell cycle G0/G1 arrest, thus facilitating virus replication, and (ii) targeting cyclin D3 to the proteasomal degradation
pathway in the cytoplasm to remove its interference with M1-M2 binding.
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TPCK-treated trypsin. Three days after incubating the plates in
an upside down manner, plaques were visualized by staining
with crystal violet (84).
Plasmids and Antibodies—Plasmid pCMV6-FLAG-CCND3
was generated by subcloning the CCND3 open reading frame
(ORF) (Homo sapiens, GenBankTM accession number NM_
001760.4) from plasmid pCMV6-CCND3-GFP (Origene Tech-
nologies) into the pCMV6-Entry vector at the MluI and SgfI
restriction sites. Plasmid pCAGGS-M2-FLAG, pCAGGS-M1-
HA, and rabbit anti-M1 polyclonal antibody (pAb) were kindly
donated by Prof. Adolfo García-Sastre (Icahn School of Medi-
cine at Mount Sinai).
The following primary antibodies were used in this study.
Mouse anti-cyclin D3 monoclonal antibody (mAb) (clone
DCS22) was purchased fromCell Signaling Technology; mouse
anti-cyclin E mAb (clone HE12), mouse anti-influenza A M2
mAb (clone 14C2), mouse anti-influenza A M1 mAb (clone
GA2B), and rabbit anti-p21 pAb were purchased from Santa
Cruz Biotechnology, Inc.; mouse anti-influenza A M2 mAb
(clone 14C2) was purchased from Thermo Scientific; mouse
anti-FLAGmAb (cloneM2) andmouse anti-c-MycmAb (clone
9E10) were purchased from Sigma-Aldrich; mouse anti-human
pRbmAb (cloneG99-549),mouse anti-Rb (ppRb Ser-780)mAb
(clone J146-35), and mouse anti-Rb (ppRb Ser-807/Ser-811)
mRb (clone J112-906) were purchased from BD Biosciences;
rabbit anti-cyclin D3 mAb (clone EP463E), mouse anti-influ-
enzaAnucleoproteinmAb (cloneAA5H),mouse anti-laminB1
mAb (clone ZL-5), and mouse anti-GAPDH mAb (clone 6C5)
were purchased from Abcam; and Texas Red-conjugated goat
anti-rabbit IgG (HL) (pAb) and FITC-conjugated goat anti-
mouse IgG (HL) (pAb) were purchased from Life Technolo-
gies, Inc.
GST Pull-down—A DNA fragment encoding the M2 gene
of influenza virus A/WSN/33 strain was cloned into the
pGEX4T-1 vector and expressed in Escherichia coli strain
BL21. The resulting GST fusion protein was purified with glu-
tathione-Sepharose beads (GE Healthcare) and added to A549
cell lysates. The empty vector expressingGST alonewas used as
negative control. After overnight incubation, beads were col-
lected by centrifugation and washed five times to remove non-
specific binding. Bound proteins were resolved by SDS-PAGE
and immunoblotting with the indicated antibodies.
Co-immunoprecipitation—HEK 293T cells were transfected
with pCMV6-FLAG-c-Myc-CCND3 plasmid in a 10-cm dish.
At 48 h post-transfection, cells were infected with influenza
A/WSN/33 strain at an MOI of 2 for 6 h before being lysed in
buffer containing 50 mM Tris (pH 7.4), 150 mM sodium chlo-
ride, 1%TritonX-100, 0.5% sodiumdeoxycholate, 1mMEDTA,
and protease inhibitors (Roche Applied Science). Cell extracts
were cleared by centrifugation, and supernatant was incubated
with anti-FLAG or isotype control antibody overnight at 4 °C.
Protein G-Sepharose beads (GE Healthcare) were then used to
recover the immune complexes from whole cell lysates. Immu-
noprecipitated samples were washed five times with lysis buffer
before being resolved by SDS-PAGE and detection byWestern
blotting.An interaction specificity studywas performed inHEK
293T cells transfected with plasmid encoding any one of the
c-Myc-tagged cyclins, D1, D2, D3, or E1, and targeted to similar
treatment as described above for co-immunoprecipitation
experiments.
For competitive binding assays, HEK 293T cells were co-
transfected with pCAGGS-M1-HA and pCAGGS-M2-FLAG
plasmids or with pCAGGS-M1-HA, pCAGGS-M2-FLAG, and
pCMV6-FLAG-cMyc-CCND3 plasmids in 10 cm dishes. Bulk
cell lysates were prepared as described above at 48 h post trans-
fection. Cleared cell extracts were incubated with anti-M2
(Santa Cruz) or isotype control antibody overnight at 4 °C, fol-
lowed by recovery of the immune complexes from whole cell
lysates using protein G-Sepharose beads. Immunoprecipitated
samples were washed six times with lysis buffer before being
resolved by SDS-PAGE and detection by Western blotting.
Synchronization of Cells—Lovastatin was used to synchro-
nize cells in G1 phase. Briefly, culture medium was removed
24 h after the initial plating of A549 cells and replaced with
fresh complete medium containing 40 M lovastatin (Sigma-
Aldrich). Cells were incubated in lovastatin for 22 h to achieve
cell cycle G0/G1 phase synchronization before other experi-
mental procedures. At time 0, cells were allowed to reenter cell
cycle progression by replacing themediumwith fresh complete
medium supplemented with 4 mM mevalonolactone (Sigma-
Aldrich). The synchronization of cells at theG2/M transition by
RO-3306 was as follows. At 24 h following plating A549 cells,
medium was replaced with fresh complete medium containing
4MRO-3306 (Calbiochem) and incubated for 18 h. Cells were
then washed three times with PBS and cultured in fresh com-
plete medium to promote cell cycle progression.
Cell Cycle Analysis—Cell cycle profiles were analyzed by
BrdU incorporation andDNA content staining. Briefly, presyn-
chronized A549 cells were infected at an MOI of 2 with influ-
enza A/WSN/33 strain or mock-infected. Immediately before
collection, cells were incubated in 10 M BrdU (Invitrogen) for
1 h and fixed overnight in 70% ethanol at	20 °C. BrdU-pulsed
cells were rescued from ethanol and denatured by 2 M hydro-
chloric acid with 0.5% Triton X-100 for 30 min at room tem-
perature, followed by neutralization with 100 mM borate
buffer (pH 8.5). BrdU labeling was revealed with Alexa Fluor
647-conjugated BrdU mouse mAb (clone MoBU-1; Invitro-
gen). Total DNA content was measured by 7-aminoactino-
mycin D (BD PharMingen) staining. Cells were then imme-
diately analyzed on a BD LSR II flow cytometer (BD
Immunocytometry Systems). Approximately 30,000 cells were
acquired for each sample, and data were analyzed using FlowJo
software (Treestar).
Protein Analysis and Proteasome Inhibition Assay—A549
cells were infected with A/WSN/33 virus at an MOI of 2 or
mock-infected. At various time points after infection, cells were
washed twice with ice-cold PBS and lysed in buffer containing
50 mM Tris (pH 7.4), 150 mM sodium chloride, 1% Triton
X-100, 0.5% sodium deoxycholate, 1 mM EDTA, and protease
inhibitors. After end-to-end rotation at 4 °C for 1 h to facilitate
lysis, cell lysateswere cleared by centrifugation at 20,817
 g for
30 min at 4 °C. Whole cell lysates were further boiled at 95 °C
for 10 min in 1
 sample loading dye and 50 mM DTT before
being subjected to SDS-PAGE.
To block ubiquitin-mediated protein degradation, A/WSN/33
virus-infected (MOI of 2) or mock-infected A549 cells were
Restriction of Influenza Infection by Cyclin D3
5084 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 12•MARCH 24, 2017
 by guest on M
ay 5, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
incubated in fresh medium containing either 40 M MG-101
(Sigma-Aldrich) or 5 M MG-132 (Sigma-Aldrich) at the start
of infection. DMSO (Sigma-Aldrich)-containing medium was
used as vehicle control in this experiment. Whole cell lysates
were collected 9 h after infection as described above.
Subcellular Fractionation—For cell fractionation, A549 cells
were infected at an MOI of 2 with influenza A/WSN/33 virus.
At 8 h p.i., cells were washed twice with ice-cold PBS and lysed
on a dish with ice-cold buffer containing 25mMTris (pH 7.4), 5
mM magnesium chloride, 150 mM sodium chloride, and 0.1%
Triton X-100. Permeabilized cells were collected with a rubber
policeman and transferred into Eppendorf tubes. After a very
brief incubation, supernatant (cytoplasm-enriched) and pellet
(nucleus-enriched) fractions were separated upon centrifuga-
tion at 20,817
 g for 30 s at 4 °C. The nuclear fraction was then
solubilized in buffer containing 25 mM Tris (pH 7.4), 5 mM
magnesium chloride, 150 mM sodium chloride, and 1% SDS.
DNA shredder was used to process the nuclear fractions to
shear the genomic DNA for easier SDS-polyacrylamide gel
loading of the samples. Sample loading dye and DTT at a final
concentration of 1
 and 50 mM, respectively, were added into
the lysate before boiling at 95 °C for 10 min.
ColocalizationAssays—To capture subcellular colocalization
between influenza M2 and cyclin D3, A549 cells were trans-
fected with a wild-type cyclin D3 plasmid (pCMV6-CCND3-
cherry). 24 h post-transfection, cellswere eithermock- or virus-
infectedwithA/WSN/33 at anMOI of 2. Cells weremaintained
inmedium supplementedwith 5MMG132 for the duration of
infection. 15 h p.i. cells were collected for the immunofluores-
cence assay.
To determine the effect of cyclin D3 on co-localization
between influenza M1 and M2, A549 cells were transfected
with either an empty vector or cyclin D3 (pCMV6-FLAG-
CCND3). 24 h post-transfection, cells were infected with influ-
enza A/WSN/33 at an MOI of 2. 10 h p.i., cells were collected
for staining and confocal imaging of influenza M1 and M2.
Immunofluorescence Assay—A549 cells were plated onto
glass coverslips 1 day before transfection or infection. Cells
were washedwith PBS and fixed in 4% paraformaldehyde for 15
min at the end of the experiments. Coverslipswere incubated in
50 mM ammonium chloride for 10 min to quench the autofluo-
rescence of paraformaldehyde before being permeabilized in
PBS containing 0.1% Triton X-100 for 10 min. Cyclin D3 was
stained with rabbit anti-cyclin D3 mAb (EP463E), followed by
incubation with FITC-conjugated goat anti-rabbit IgG. The
viralM2 protein was visualized by labeling withmouse anti-M2
mAb (14C2), followed by staining with Texas Red-conjugated
goat anti-mouse IgG. The viral M1 protein was visualized by
labelingwith rabbit anti-M1pAb, followedby FITC-conjugated
goat anti-rabbit IgG. After washing with PBS, coverslips were
incubated with DAPI for nucleus staining and mounted in
Mowiol on glass slides. Images were acquired with a Zeiss LSM
700 confocal fluorescence microscope at the Faculty Imaging
Core Facility of the University of Hong Kong.
RNA Interference and Virus Infection—All gene-specific
siRNAs were purchased from Dharmacon (Dharmacon Re-
search). Individual siRNAs against the 5-AAGGAUCUUUG-
UGGCCAAGGA-3 sequence (62) or 5-UGCGGAAGAUGC-
UGGCUUA-3 (D-003212-08) sequence of human cyclin D3
transcript and the nontargeting siRNA (D-001210) were used.
siRNAs for human cyclin E1 transcript (M-003213) and human
Rb1 transcript (M-003296) were provided as an siGENOME
SMARTpool containing amixture of four siRNAs targeting dif-
ferent sites of a single gene. A549 cells were transfected with
siRNAs (final concentration of 100 mM for each gene) by using
DharmaFECT 1 transfection reagent according to the manufac-
turer’s protocol. Cells were subcultured 48 h post-transfection
to avoid potential cell cycle arrest induced by overconfluence.
To study the effect of gene knockdown on influenza progeny
virus production, siRNA-treated A549 cells or HBECs were
infected with influenza viruses 24 h after seeding at an MOI of
0.01 in DMEM containing 0.3% BSA (Sigma-Aldrich), in the
presence of 0.1 g/ml TPCK-treated trypsin (Thermo Scien-
tific). Supernatants were collected at 24 and 48 h p.i., and the
progeny virus titers were obtained by a plaque assay as
described above. Separate wells without infection were used to
determine the knockdown efficiency by Western blotting.
The effect of siRNA treatment on influenza viral protein
expression was investigated in cells prepared as described
above. Cells were infected with A/WSN/33 virus at anMOI of 2
and supplied with fresh cell culture medium containing 10%
FBS and 100 units/ml penicillin and 100 g/ml streptomycin
after removing the virus inoculums. Whole cell lysates were
prepared from individual wells at 3, 6, 9, and 12 h p.i. forWest-
ern blotting analysis.
Cyclin D3-specific siRNA-treated and control A549 cells
were infected at anMOI of 1 with A/WSN/33 virus to study the
effect of cyclin D3 reduction onM2 plasma membrane expres-
sion. To synchronize viral entry, cells were incubatedwith virus
at 4 °C for 1 h and replaced with prewarmed fresh cell culture
medium. Virus-infected cells were collected and fixed at 6 and
8 h p.i. for surfaceM2 expression detection using anti-M2mAb
(Thermo Scientific) followed by FITC-conjugated secondary
antibody without permeabilization. Cells were then immedi-
ately analyzed on a BD LSR II flow cytometer (BD Immunocy-
tometry Systems). Approximately 30,000 cells were acquired
for each sample, and data were analyzed using FlowJo software
(Treestar).
Absolute Quantitative RT-PCR—Gene expression patterns
were determined by two-step RT-PCRs. Briefly, total RNA was
isolated from around 1 
 105 HBECs and pneumocytes using
an RNeasy Plus kit in combination withQIAshredder (Qiagen).
cDNAwas then generated from the total RNA using the Super-
Script III first-strand synthesis system (Invitrogen) according
to the manufacturer’s recommendation. The cDNA product
was used undiluted for HBECs or 20-fold diluted for pneumo-
cytes. Serial dilutions of plasmids of cyclin D1, D2, D3, and E1
with known gene copy numbers were used to generate standard
curves for absolute quantification of the desired gene expres-
sion. The real-time PCRs were performed in 25-l reactions
containing fluorigenic Taqman probe at a final concentration
of 400nM togetherwith an 800nMconcentration of each primer
and 12.5 l of 2
 Probe Master (Roche Applied Science). The
assays were performed on the LightCycler 480 II (Roche
Applied Science) with thermal cycling conditions of 10 min at
95 °C followed by 40 cycles of 95 °C for 10 s, 60 °C for 1min, and
Restriction of Influenza Infection by Cyclin D3
MARCH 24, 2017•VOLUME 292•NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 5085
 by guest on M
ay 5, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
72 °C for 1 s. Each sample was quantified in triplicate for each
experiment. Primers and probes were as follows: 5-CTGTCC-
TACTACCGCCTCACA-3 (forward), 5-GCCTTGGGGTC-
CATGTTCT-3 (reverse), and 5-(FAM)CCAGAGTGATCA-
AGTGTGACCCAGACTGCC(TAMRA)-3 (Taqman probe)
for cyclin D1 (85); 5-GGGAACTGGTGGTGCTGG-3 (for-
ward), 5-TGGGTACATGGCAAACTTAAAGTC-3 (reverse),
and 5-(FAM)AAGCTGTCTCTGATCCGCAAGCATGC(TA-
MRA)-3 (Taqman probe) for cyclin D2 (85); 5-TCCGGGGAT-
GAGCTCACAGA-3 (forward), 5-GGCTCTCCCTGAGTGC-
AGCTT-3 (reverse), and 5-(FAM)TGGCAGGGATCACTGG-
CACTGAAGTGGACT(TAMRA)-3 (Taqman probe) for cyclin
D3 (85); 5-GAAGATGATGACCGGGTTTAC-3 (forward), 5-
GAGCCTCTGGATGGTGCAA-3 (reverse), and 5-(FAM)
CAAACTCAACGTGCAAGCCTCGGAT(TAMRA)-3 (Taq-
man probe) for cyclin E1 (86).
Statistical Analysis—Results are shown asmean S.D. of the
indicated number of experiments. Statistical difference be-
tween groups was determined by unpaired Student’s t test or
two-way ANOVA, with a 0.05 significance level.
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